Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,728 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Treatment of Pleural Mesothelioma: ASCO Guideline Update.
Kindler HL, Ismaila N, Bazhenova L, Chu Q, Churpek JE, Dagogo-Jack I, Bryan DS, Drazer MW, Forde P, Husain AN, Sauter JL, Rusch V, Bradbury PA, Cho BCJ, de Perrot M, Ghafoor A, Graham DL, Khorshid O, Lebensohn A, White J, Hassan R. Kindler HL, et al. Among authors: cho bcj. J Clin Oncol. 2025 Jan 8:JCO2402425. doi: 10.1200/JCO-24-02425. Online ahead of print. J Clin Oncol. 2025. PMID: 39778125
FURVENT: Phase 3 trial of firmonertinib vs chemotherapy as first-line treatment for advanced NSCLC with EGFR exon 20 insertion mutations (FURMO-004).
Spira A, Cho BC, Felip E, Garon EB, Goto K, Johnson M, Leighl N, Passaro A, Planchard D, Popat S, Yang JC, Lu X, Jiang Y, Huang J, Lam M, Kowanetz M, Wang S, Le J, Hsu JY, Zhou CC. Spira A, et al. Among authors: cho bc. Lung Cancer. 2024 Dec 28;199:108066. doi: 10.1016/j.lungcan.2024.108066. Online ahead of print. Lung Cancer. 2024. PMID: 39764938 Review. No abstract available.
Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.
Yoo SK, Fitzgerald CW, Cho BA, Fitzgerald BG, Han C, Koh ES, Pandey A, Sfreddo H, Crowley F, Korostin MR, Debnath N, Leyfman Y, Valero C, Lee M, Vos JL, Lee AS, Zhao K, Lam S, Olumuyide E, Kuo F, Wilson EA, Hamon P, Hennequin C, Saffern M, Vuong L, Hakimi AA, Brown B, Merad M, Gnjatic S, Bhardwaj N, Galsky MD, Schadt EE, Samstein RM, Marron TU, Gönen M, Morris LGT, Chowell D. Yoo SK, et al. Among authors: cho ba. Nat Med. 2025 Jan 6. doi: 10.1038/s41591-024-03398-5. Online ahead of print. Nat Med. 2025. PMID: 39762425
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study.
Sands J, Ahn MJ, Lisberg A, Cho BC, Blumenschein G Jr, Shum E, Pons Tostivint E, Goto Y, Yoh K, Heist R, Shimizu J, Lee JS, Baas P, Planchard D, Pérol M, Felip E, Su WC, Zebger-Gong H, Lan L, Liu C, Howarth P, Chiaverelli R, Paz-Ares L. Sands J, et al. Among authors: cho bc. J Clin Oncol. 2025 Jan 6:JCO2401349. doi: 10.1200/JCO-24-01349. Online ahead of print. J Clin Oncol. 2025. PMID: 39761483
Amivantamab Plus Lazertinib in Patients With EGFR-mutant Non-small Cell Lung Cancer (NSCLC) After Progression on Osimertinib and Platinum-based Chemotherapy: Results From CHRYSALIS-2 Cohort A.
Besse B, Goto K, Wang Y, Lee SH, Marmarelis ME, Ohe Y, Caro RB, Kim DW, Lee JS, Cousin S, Ichihara E, Li Y, Paz-Ares L, Ono A, Sanborn RE, Watanabe N, Jose de Miguel M, Helissey C, Shu CA, Spira AI, Tomasini P, Chih-Hsin Yang J, Zhang Y, Felip E, Griesinger F, Waqar SN, Calles A, Neal JW, Baik CS, Jänne PA, Shreeve SM, Curtin JC, Patel B, Gormley M, Lyu X, Chen J, Chu PL, Mahoney J, Trani L, Bauml JM, Thayu M, Knoblauch RE, Cho BC. Besse B, et al. Among authors: cho bc. J Thorac Oncol. 2025 Jan 2:S1556-0864(24)02550-4. doi: 10.1016/j.jtho.2024.12.029. Online ahead of print. J Thorac Oncol. 2025. PMID: 39755170 Free article.
4,728 results